PHA-680626

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NamePHA-680626
Drug Alias NamePHA-680626
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNerviano Medical Sciences Srl
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNerviano Medical Sciences Srl
Active IndicationsN/A
Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksN/A